-
UNITED THERAPEUTICS CORPORATION v. SANDOZ, INC. DC CAFC
- 3:12-cv-01617
- D.N.J.
- Judge: Peter G. Sheridan
+1
- Filed: 03/14/2012
- Closed: 08/29/2014
- Latest Docket Entry: 01/12/2016
- PACER
1
Plaintiff
2
Defendants
1
Accused
Product
3
Patents-in-Suit
899
Days in
Litigation
-
UNITED THERAPEUTICS CORPORATION v. SANDOZ, INC. DC CAFC
- 3:12-cv-01617
- D.N.J.
- Judge: Peter G. Sheridan
+1
- Filed: 03/14/2012
- Closed: 08/29/2014
- Latest Docket Entry: 01/12/2016
- PACER
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A method of selectively killing gram negative bacteria and inhibiting the growth of gram positive bacteria in a pharmaceutical preparation comprising an active agent selected from the group consisting of treprostinil and treprostinil sodium, the
view more
|
Valid
Entry 161 |
2 |
The method of claim 1, wherein the active agent is treprostinil sodium.
|
Valid
Entry 161 |
3 |
The method of claim 1, wherein the buffer further comprises sodium hydroxide.
|
Valid
Entry 161 |
4 |
The method of claim 1, wherein the buffer has a pH between about 10 to about 12 with low buffer capacity.
|
Valid
Entry 161 |
5 |
The method of claim 4, wherein the buffer has a pH between about 10.2 to about 10.8 with low buffer capacity.
|
Valid
Entry 161 |
7 |
The method of claim 1, wherein the active agent is supplied at a concentration between about 0.001 mg/mL to about 1 mg/mL.
|
Valid
Entry 161 |
8 |
The method of claim 2, wherein the treprostinil sodium is supplied at a concentration between about 0.004 mg/mL to about 0.13 mg/mL.
|
Valid
Entry 161 |
9 |
The method of claim 1 further comprising injecting the pharmaceutical preparation into a mammal in need thereof.
|
Valid
Entry 161 |
10 |
The method of claim 4, wherein the pharmaceutical preparation is injected intravenously into a mammal in need thereof.
|
Valid
Entry 161 |
11 |
A method of reducing the occurrence of blood stream infections in a mammal being treated with an active agent comprising administering to the mammal the active agent with a buffer comprising glycine and having a pH of greater than 10, wherein the
view more
|
Valid
Entry 161 |
12 |
The method of claim 11, wherein the human subject has pulmonary arterial hypertension.
|
Valid
Entry 161 |
13 |
The method of claim 11, where in the active agent is administered intravenously.
|
Valid
Entry 161 |
14 |
The method of claim 11, wherein the active agent is treprostinil sodium.
|
Valid
Entry 161 |
15 |
The method of claim 11, wherein the buffer further comprises sodium hydroxide and has a pH between about 10.2 to about 10.8.
|
Valid
Entry 161 |
16 |
The method of claim 11, wherein the buffer has a pH between about 10 to about 12 with low buffer capacity.
|
Valid
Entry 161 |
17 |
The method of claim 16, wherein the buffer has a pH between about 10.2 to about 10.8 with low buffer capacity.
|
Valid
Entry 161 |
19 |
The method of claim 11, wherein the active agent is supplied at a concentration between about 0.004 mg/mL to about 0.13 mg/ml.
|
Valid
Entry 161 |
20 |
The method of claim 14, wherein the treprostinil sodium is supplied at a concentration between about 0.004 mg/mL to about 0.13 mg/mL.
|
Valid
Entry 161 |
21 |
The method of claim 1 wherein the administering is injecting the pharmaceutical preparation into a mammal in need thereof.
|
Valid
Entry 161 |
23 |
The composition of claim 22, wherein the solution further comprises sodium hydroxide.
|
Valid
Entry 161 |
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A stereoselectively produced isomeric compound according to the following formula: <CWU><CHEM-US ID="CHEM-US-00026"><CHEMCDX ID="CHEMCDX-00026" ALT="chemistry chemdraw file" FILE="US06765117-20040720-C00026.CDX"/><CHEMMOL ID="CHEMMOL-00026"
view more
|
Valid
Entry 161 |
2 |
The stereoselectively produced isomeric compound of claim 1, wherein Z is O, n is 1, X is COOH, Y<HIL><SB>1 </SB></HIL>is -CH<HIL><SB>2</SB></HIL>CH<HIL><SB>2</SB></HIL>- M<HIL><SB>1 </SB></HIL>is α-OH:β-R<HIL><SB>5</SB></HIL>, wherein R<HIL><SB>5
view more
|
Valid
Entry 161 |
3 |
A steroselectively produced isomeric compound according to the following formula: <CWU><CHEM-US ID="CHEM-US-00029"><CHEMCDX ID="CHEMCDX-00029" ALT="chemistry chemdraw file" FILE="US06765117-20040720-C00029.CDX"/><CHEMMOL ID="CHEMMOL-00029"
view more
|
Valid
Entry 161 |
4 |
A steroselectively produced isomeric compound in pharmacologically acceptable salt form according to the following formula: <CWU><CHEM-US ID="CHEM-US-00032"><CHEMCDX ID="CHEMCDX-00032" ALT="chemistry chemdraw file"
view more
|
Valid
Entry 161 |
-
Infringement
Sandoz Inc.
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic copy of REMODULIN treprostinil sodium injection 200mg/20mL (10mg/mL)Remodulin treprostinil sodium injection | US 6,765,117 B2 |
1, 2, 3, 4
|
Infringement
Entry 161Entry 162 |
Generic copy of REMODULIN treprostinil sodium injection 200mg/20mL (10mg/mL)Remodulin treprostinil sodium injection | US 7,999,007 B2 |
1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21, 23
|
No infringement
Entry 161Entry 162 |